KNACK Trademark

Trademark Overview


On Thursday, March 1, 2018, a trademark application was filed for KNACK with the United States Patent and Trademark Office. The USPTO has given the KNACK trademark a serial number of 87816982. The federal status of this trademark filing is REGISTERED as of Tuesday, October 26, 2021. This trademark is owned by KNACK PHARMACEUTICALS, INC.. The KNACK trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of epilepsy disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment ...
knack

General Information


Serial Number87816982
Word MarkKNACK
Filing DateThursday, March 1, 2018
Status700 - REGISTERED
Status DateTuesday, October 26, 2021
Registration Number6540122
Registration DateTuesday, October 26, 2021
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 17, 2018

Trademark Statements


Goods and ServicesPharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of epilepsy disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of skin diseases, allergies and rheumatic disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of Alzheimer; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of ophthalmic related disorders and diseases; Pharmaceutical preparations for the treatment and prevention of musculoskeletal related diseases and disorders; Pharmaceutical preparations for for the treatment and prevention of metabolic, endocrine and kidney related diseases and disorders; Pharmaceutical preparations for the support and promotion of bone strength and health; Pharmaceutical preparations for the treatment of bone disorders and bone diseases; Pharmaceutical preparations for the treatment of toxic effects; Pharmaceutical preparations for use as injectable anesthetics; Pharmaceutical preparations for use as contraceptives; Pharmaceutical preparations for fertility enhancement purposes; Pharmaceutical preparations for use in hormone replacement therapy; Pharmaceutical preparations for the prevention and treatment of hormone disorders and deficiencies; Pharmaceutical preparations for inducing labor and facilitating nursing; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for for the prevention and treatment of nausea and vomiting; Pharmaceutical preparations for the prevention and treatment of aids-related disorders and diseases; Pharmaceutical preparations for treatment and prevention of viral and bacterial infections; Pharmaceutical preparations, namely, injectable contraceptives

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, March 8, 2018
Primary Code005
First Use Anywhere DateSunday, August 1, 2021
First Use In Commerce DateSunday, August 1, 2021

Trademark Owner History


Party NameKNACK PHARMACEUTICALS, INC.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressNew York City, NY 10022

Party NameKNACK PHARMACEUTICALS, INC.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York City, NY 10022

Party NameKNACK PHARMACEUTICALS, INC.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York City, NY 10022

Trademark Events


Event DateEvent Description
Wednesday, November 17, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, November 17, 2021TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Wednesday, November 17, 2021ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, November 17, 2021TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, October 26, 2021REGISTERED-PRINCIPAL REGISTER
Saturday, September 18, 2021NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Friday, September 17, 2021ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Thursday, September 16, 2021STATEMENT OF USE PROCESSING COMPLETE
Friday, September 10, 2021USE AMENDMENT FILED
Friday, September 10, 2021TEAS STATEMENT OF USE RECEIVED
Wednesday, March 17, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, March 16, 2021EXTENSION 5 GRANTED
Tuesday, March 2, 2021EXTENSION 5 FILED
Tuesday, March 16, 2021CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, March 2, 2021TEAS EXTENSION RECEIVED
Saturday, August 8, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, August 6, 2020EXTENSION 4 GRANTED
Thursday, August 6, 2020EXTENSION 4 FILED
Thursday, August 6, 2020TEAS EXTENSION RECEIVED
Saturday, March 7, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, March 5, 2020EXTENSION 3 GRANTED
Thursday, March 5, 2020EXTENSION 3 FILED
Thursday, March 5, 2020TEAS EXTENSION RECEIVED
Friday, August 30, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, August 28, 2019EXTENSION 2 GRANTED
Wednesday, August 28, 2019EXTENSION 2 FILED
Wednesday, August 28, 2019TEAS EXTENSION RECEIVED
Tuesday, March 5, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, March 1, 2019EXTENSION 1 GRANTED
Friday, March 1, 2019EXTENSION 1 FILED
Friday, March 1, 2019TEAS EXTENSION RECEIVED
Tuesday, September 11, 2018NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, July 17, 2018OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 17, 2018PUBLISHED FOR OPPOSITION
Wednesday, June 27, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, June 13, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, June 13, 2018ASSIGNED TO EXAMINER
Thursday, March 8, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, March 5, 2018NEW APPLICATION ENTERED IN TRAM